ArticleBiomarker research2026
Machine learning-driven proteomics classifier deciphers tumor origins of primary and metastatic squamous cell carcinomas.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.Biomarker research · 2026Review
- The Oncogenic Role of Long Non-Coding RNABiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
Squamous cell carcinoma (SCC) occurs across multiple organs with highly similar histology, making the diagnosis of SCC of unknown primary (SCCUP) particularly challenging. To address this, we established a machine learning–based 39-protein biomarker classifier (39PBC) trained on proteomic profiles from 387 SCC samples collected at seven tertiary hospitals. The classifier accurately predicted the origin of primary and metastatic SCCs from cervical, esophageal, lung, nasopharyngeal, and head and neck sites, with validation in internal (n = 324) and external (n = 63) cohorts yielding AUCs of 0.924–0.961 and 0.971 and accuracies above 87%. Immunohistochemistry of 509 cases further identified a simplified five-marker panel (four robust site-specific markers CCDC6, LGALS7, LGALS9, and P16, together with EBER) suitable for routine screening. Importantly, 39PBC demonstrated reliable performance in real-world SCCUP and dual-primary cases. Proteomic profiling also uncovered distinct prognostic and molecular landscapes, implicating metabolic activation as a driver of progression and immune modulation as a site-specific feature. Together, these findings establish a clinically applicable workflow that integrates high-resolution proteomics with practical IHC validation, offering a public resource to improve SCCUP diagnosis, enable cost-effective clinical translation, and provide mechanistic insights into SCC metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.